Pure Global AI
NCT06403111Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Fecal Microbiota Transplantation Combined With Immunotherapy and Chemotherapy as First-line Treatment for Driver-gene Negative Advanced Non-small Cell Lung Cancer: a Prospective, Multicenter, Single-arm Exploratory Study (FMT-JSNO-02)
Changzhou No.2 People's HospitalPhase 2ClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
Changzhou No.2 People's Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jun 01, 2026
Enrollment
62 participants
Primary outcome

12-Months Progression-Free Survival Rate (12month-PFS)

Summary

This study plans to reconstruct intestinal microecology through fecal microbiota
 transplantation (FMT), and combine first-line standard therapy to enhance the anti-tumor
 immune effect at the same time, thereby extending the progression-free survival of patients
 and improving the prognosis of patients.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06403111
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06403111 through Pure Global AI's free database. This Phase 2 trial is sponsored by Changzhou No.2 People's Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 62 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.